CompuGroup Medical SE & Co. KGaA
- WKN: A28890
- ISIN: DE000A288904
- Land: Deutschland
Nachricht vom 14.09.2021 | 16:45
CompuGroup Medical SE & Co. KGaA announces medium-term targets for EBITDA-margin for the first time
CompuGroup Medical SE & Co. KGaA / Key word(s): Forecast
CompuGroup Medical SE & Co. KGaA ("CompuGroup Medical") announces medium-term targets for the development of the adjusted EBITDA-margin for the first time. The medium-term growth target of increasing group revenues year-on-year organically by 5 percent and more per year from 2021 through 2025 had been published previously. In addition, today the managing directors of the general partner CompuGroup Medical Management SE ("Managing Directors") have also concluded and adopted specific targets from the ongoing planning process with regard to the medium-term increase in adjusted EBITDA-margin for the first time. Accordingly, CompuGroup Medical aims to increase the adjusted EBITDA margin to approximately 25 % in 2023 and approximately 27 % in 2025. Further information on medium-term targets will be presented at tomorrow's virtual Capital Markets Day.
In light of the ongoing investment program announced in December 2020 to accelerate growth, the Managing Directors confirm the full year 2021 guidance. CompuGroup Medical expects revenues in 2021 to be in a range of € 1 billion and € 1.04 billion as well as adjusted EBITDA between € 210 million and € 230 million.
Explanation of financial figures:
The financial figure of adjusted operating profit (adjusted EBITDA) is not a figure defined in accordance with International Financial Reporting Standards (IFRS). It includes earnings before interest, taxes, depreciation and amortization, adjusted by the effects of major acquisitions and disposals of subsidiaries, business units and shareholdings, amortization as well as write-ups of shareholdings, effects from the acquisition, construction and sale of real estate, amortization and write-ups on owner-occupied real estate as well as expenses in connection with share-based compensation programs of the Managing Directors, as well as other non-operating or non-period-related non-recurring effects.
Adjusted EBITDA-margin is calculated by dividing adjusted EBITDA by group revenue.
This release contains "forward-looking statements". Forward-looking statements may differ significantly from future results and often in fact differ. All forward-looking statements reflect CompuGroup Medical SE & Co. KGaA's ("CompuGroup Medical") current view on future events and are subject to risks relating to future events and other risks, uncertainties and assumptions regarding CompuGroup Medical's business, financial position, results of operations, liquidity, prospects, growth or strategy. Forward-looking statements should always be considered from the perspective of the date on which they are made. CompuGroup Medical as well as their affiliated companies expressly disclaim any obligation to update, review or adjust any forward-looking statements contained in this release as a result of new information, future developments or other reasons. Any responsibility for the future accuracy of the forward-looking statements expressed in this release or the actual occurrence of the forecast developments is expressly excluded.
|Company:||CompuGroup Medical SE & Co. KGaA|
|Maria Trost 21|
|Phone:||+49 (0)261 8000 7030|
|Fax:||+49 (0)261 8000 3200|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1233329|
|End of Announcement||DGAP News Service|
CompuGroup Medical SE & Co. KGaA: Release of a ...
CompuGroup Medical SE & Co. KGaA adopts resolu ...
CGM confirms guidance after strong third quarter
CompuGroup Medical extends contract with CFO M ...
CompuGroup Medical SE & Co. KGaA: Preliminary ...
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
02. Dezember 13:15 Daimler: Aktie auf Erholungskurs?
02. Dezember 13:32 Comeback-Chance Fortec Elektronik: Ausblick macht Lust auf mehr – ...
02. Dezember 13:46 Hugo Boss: Verflüchtigt sich nun die Laufkundschaft?
02. Dezember 13:47 Teamviewer: Der Abverkauf geht weiter
02. Dezember 13:51 Dow Jones: Der dritte Versuch....
News im Fokus
Linde Included in Dow Jones Sustainability World Index for 19th Consecutive Year
02. Dezember 2021, 12:00
FY 2020/2021 Financial Results
16. Dezember 2021
Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen
02. Dezember 2021